Jounce Therapeutics, Inc. (JNCE) News

Jounce Therapeutics, Inc. (JNCE): $4.71

0.19 (+4.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add JNCE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 395

in industry

Filter JNCE News Items

JNCE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

JNCE News Highlights

  • For JNCE, its 30 day story count is now at 5.
  • Over the past 20 days, the trend for JNCE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • BCRX, BEAT and ORGO are the most mentioned tickers in articles about JNCE.

Latest JNCE News From Around the Web

Below are the latest news stories about Jounce Therapeutics Inc that investors may wish to consider to help them evaluate JNCE as an investment opportunity.

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -29.03% and 2.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Jounce Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Wednesday, March 2, 2022

CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update before market open on Wednesday, March 2, 2022. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m. ET. Conference Call

Yahoo | February 23, 2022

Analysts Estimate Jounce Therapeutics, Inc. (JNCE) to Report a Decline in Earnings: What to Look Out for

Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Organogenesis (ORGO) Stock Jumps 7.4%: Will It Continue to Soar?

Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Yahoo | February 16, 2022

Jounce Therapeutics (NASDAQ:JNCE) Is In A Strong Position To Grow Its Business

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | February 3, 2022

Jounce Therapeutics (JNCE) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | January 15, 2022

Jounce Therapeutics to Present at Upcoming Investor Conferences in January

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at the following upcoming investor conferences in January: H.C. Wainwright BioConnect Virtual Conference: Presentation will be available for on-demand viewing starting on January 10, 2022 at 7:00 a.m. ET.40th Annual J.P. Mor

Yahoo | January 4, 2022

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Sold by Ziegler Capital Management LLC

Ziegler Capital Management LLC cut its holdings in shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE) by 3.3% during the third quarter, Holdings Channel.com reports. The fund owned 68,780 shares of the companys stock after selling 2,317 shares during the period. Ziegler Capital Management LLCs holdings in Jounce Therapeutics were worth $511,000 at the end of the []

Dakota Financial News | December 18, 2021

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Receives $15.67 Consensus Target Price from Brokerages

Jounce Therapeutics, Inc. (NASDAQ:JNCE) has earned a consensus recommendation of Buy from the seven brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokerages that have []

Dakota Financial News | December 15, 2021

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Purchased by State Street Corp

State Street Corp boosted its stake in Jounce Therapeutics, Inc. (NASDAQ:JNCE) by 43.3% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 438,765 shares of the companys stock after acquiring an additional 132,486 shares during the quarter. State Street Corp owned 0.86% of Jounce Therapeutics worth $2,984,000 []

Transcript Daily | December 2, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4541 seconds.